Trizivir · DIN 02244757 · 300 mg & 150 mg & 300 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2019-09-17 — choose a marketed DIN from the same-category list.Discontinued September 17, 2019 · checked November 18, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2019-09-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2019-09-17 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Trizivir · DIN 02244757
Manufacturer: ViiV Healthcare ULC; listing date 2003-01-30
Health Canada: Cancelled post market since 2019-09-17 · brand TRIZIVIR · ATC J05AR04 ZIDOVUDINE, LAMIVUDINE AND ABACAVIR · form Tablet · route Oral · ingredients ABACAVIR (ABACAVIR SULFATE) 300 MG, LAMIVUDINE 150 MG, ZIDOVUDINE 300 MG · company Viiv healthcare ulc · schedule Prescription
Ministry pays: $13.6425 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244757)
Source record
DIN 02244757: Trizivir
Raw flags: sec3=Y
Item: 081800065; group id 59; item number 0118; lccId None; manufacturer id VIH
Source form: Tab; strength: 300mg & 150mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $19.0426; ministry $13.6425
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244757
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68746
Interchangeable products
Apo-Abacavir-Lamivudine-Zidovudine · DIN 02416255 · $13.6425
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since September 17, 2019 — choose a marketed DIN from the same-category list.